⌘K
t
On 31 July 2023, Destiny Pharma plc announced the publication of new data in the journal Infection & Drug Resistance, evaluating its antibacterial drug XF-73 against MRSA in skin infection models. The study reported XF-73 was 100 times more effective than mupirocin, achieving a >3 log10 CFU/mL reduction in MRSA infection compared to mupirocin's <1 log10 reduction. This research, partly funded by a £1.6m collaboration involving Destiny Pharma, China Medical System Holdings Limited, Cardiff University, and Tianjin Medical University, also noted XF-73 achieved its results at a 0.2% (w,w) concentration versus mupirocin's 2% (w,w).
| Date | 31 Jul 2023 |
| Time | 12:01:33 |
| Category | Miscellaneous |
| ID | 7558H |
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Publication of new data demonstrates significantly superior efficacy of XF-73 compared to a leading topical antibiotic against MRSA in skin infection models
Brighton, United Kingdom - 31 July 2023 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and treat life threatening infections, today announces the publication of new data in the journal Infection & Drug Resistance from a study evaluating the potency of Destiny Pharma's antibacterial drug, XF-73, against methicillin-resistant Staphylococcus aureus (MRSA) in two, industry-standard, skin infection models and comparing its efficacy against mupirocin, a leading topical antibiotic.
The publication, entitled, "Efficacy of a Novel Antibacterial Agent Exeporfinium Chloride, (XF‑73), against Antibiotic-Resistant Bacteria in Superficial Skin Infection Models" concluded that:
· XF-73 dermal formulation was 100 times more effective at killing MRSA (USA 300 strain) than the topical antibiotic mupirocin, in two skin infection models
o Single doses of XF-73 and mupirocin reduced MRSA infection by >3 log10 CFU/mL (p<0.0001) and <1 log10, (p<0.05) respectively, relative to control (no treatment)
· XF-73 had significantly greater statistical efficacy than mupirocin in both MRSA skin infection models, (p<0.0001)
· Mupirocin had little or no impact on mupirocin resistant-MRSA strains in the skin infection model, even following 2 doses, whereas XF-73's potency was not impaired and was equally effective against the mupirocin-resistant MRSA strains, maintaining a >3 log10 reduction of this superbug
· XF-73 further demonstrated its potency by achieving these results at a concentration of 0.2% (w,w), compared to 2% (w,w) marketed mupirocin ointment i.e. at 10 times less relative concentration.
Destiny Pharma's partner, China Medical System Holdings Limited (CMS) is developing the XF-73 dermal formulation as a treatment for superficial skin infections through its relationship with Tianjin Medical University.
The global acute bacterial skin and skin structure infections market is estimated to be valued at US$ 3,466 million in 2022 and is expected to exhibit a CAGR of 6.0% over the forecast period (2022-2030).1
Destiny Pharma has cross-reference rights to data generated from the programme and so retains the option to develop dermal XF-73 products for US, European, Japanese and other territories outside those held by CMS (mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and other certain Asian countries/regions).
This research project was partly funded through a £1.6m collaboration between Destiny Pharma, Cardiff University, CMS and Tianjin Medical University. The collaboration was established under the UK-China antimicrobial resistance (AMR) grant fund set up by Innovate UK and the Department of Health with the Chinese Ministry of Science and Technology.
Dr Bill Love, Chief Scientific Officer of Destiny Pharma, said: "This dataset is compelling and demonstrates clear and significant advantages for XF-73 over one of the world's leading topical antibiotics, mupirocin. It adds further impetus for the clinical development of XF-73 to treat skin infections for CMS and Destiny Pharma. It also provides a valuable additional read across of comparative activity against MRSA and mupirocin-resistant strains which are a growing cause of post-surgical infections and is therefore supportive of our XF-73 nasal gel product."
Dr Debra Barker, Interim Chief Executive Officer of Destiny Pharma, said: "The publication of these new data provides further evidence of the superiority of XF-73 over the leading standard of care and is highly relevant to our strategy to advance the product across a range of indications. Working with CMS in this Innovate UK-backed collaboration has many benefits, not least to our ability to cross-reference these data, and we look forward to sharing further progress."
Dr Phil Packer, Innovation Lead for AMR at Innovate UK, added: "I am very excited to see the outputs from this productive international collaborative project. It demonstrates great commercial potential in the area of AMR where there is a dire need for novel therapeutics such as XF-73."
- END -
For further information, please contact:
Destiny Pharma plc
Debra Barker, Interim CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
[email protected]
Powerscourt Group
Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward
+44 (0) 20 7250 1446
finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.
For further information on the company, please visit www.destinypharma.com
About XF-73
XF-73 is the lead drug candidate from Destiny Pharma's XF platform, initially being developed for the prevention of post-surgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA), which cause significant complications and increased healthcare costs in the hospital setting. XF‑73 has been awarded both Qualified Infectious Disease Product (QIDP) and Fast Track status by the US FDA.
Dermal Infections
XF-73 is being developed as a new treatment for serious dermal infections such as diabetic foot ulcer infections (DFUs) to target a market which is estimated to be a $0.5 billion global sales opportunity based on the incidence of such infections, the costs of the associated medical care and a realistic product pricing of XF-73 in this new market. Driven by the growing number of diabetics and associated complications such as infected DFUs, this represents a significant market opportunity for XF-73. It is estimated that twenty-nine million people in US have a diagnosis of diabetes and of these 13% have active DFUs.
As with all anti-infectives, AMR is also a concern within this market. There is no dominant treatment for DFUs, and specialist physicians are therefore working to find better treatment options, including topical formulations. In addition, the target product profile of XF-73 tested favourably with dermal clinicians looking for better treatments for the smaller market for burns/wound infections and venous leg ulcers.